MSC^E116K augments expression of the CD30–IRF4–MYC axis in normal and neoplastic T cells. (A) Expression of the TNFRSF8 gene encoding CD30 is increased in normal T cells transduced with MSC^E116K. Data are from RNAseq. Representative results from 2 independent experiments. (B) CD30 protein expression is increased in normal T cells transduced with MSC^E116K. (C) Heat map showing downregulation of E2F2 and upregulation of genes involved in the CD30–IRF4–MYC axis in response to MSC^E116K in normal CD4⁺ T cells. Data are from RNAseq. Representative results from 2 independent experiments. (D) Expression levels of TNFRSF8 and MYC are increased in Karpas 299 cells transduced with MSC^E116K. These RNAseq data are from the same experiment shown in Figure 4B. Representative results from 2 independent experiments. (E) Overexpression of E2F2 in Karpas 299 cells decreases expression of CD30 and MYC. Data are from flow cytometry. Representative results from 3 independent experiments. (F) IRF4 knockdown in ALCL cell lines decreases MSC expression. (G) IRF4 ChIP-seq demonstrates binding of IRF4 to the MSC locus 2.3 kb downstream and 2.4 kb and 7.2 kb upstream of the transcriptional start site in ALCL cell lines. MSC-AS1 is a noncoding RNA gene that was minimally expressed at the RNA level and showed no significant differential expression after IRF4 knockdown. RPKM, reads per kilobase of transcript per million mapped reads.